Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/73—Unsubstituted amino or imino radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/56—Amides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/61—Halogen atoms or nitro radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/84—Nitriles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
  • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
  • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Definitions

• the invention relates to heterocyclic derivatives, or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals.
• the invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.
• Factor Xa is one of a cascade of proteases involved in the complex process of blood coagulation.
• the protease known as thrombin is the final protease in the cascade and Factor Xa is the preceding protease which cleaves prothrombin to generate thrombin.
• the compounds of the present invention possess activity in the treatment or prevention of a variety of medical disorders where anticoagulant therapy is indicated, for example in the treatment or prevention of thrombotic conditions such as coronary artery and cerebro-vascular disease.
• medical disorders include various cardiovascular and cerebrovascular conditions such as myocardial infarction, the formation of atherosclerotic plaques, venous or arterial thrombosis, coagulation syndromes, vascular injury including reocclusion and restenosis following angioplasty and coronary artery bypass surgery, thrombus formation after the application of blood vessel operative techniques or after general surgery such as hip replacement surgery, the introduction of artificial heart valves or on the recirculation of blood, cerebral infarction, cerebral thrombosis, stroke, cerebral embolism, pulmonary embolism, ischaemia and angina (including unstable angina).
• the compounds of the invention are also useful as inhibitors of blood coagulation in an ex - vivo situation such as, for example, the storage of whole blood or other biological samples suspected to contain Factor Xa and in which coagulation is detrimental.
• the present invention provides compounds of formula (I) A-B-X 1 -T 1 (R 2 )-L 1 -T 2 (R 3 )-X 2 -Q wherein:
• alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl” are specific for the straight chain version only. An analogous convention applies to other generic terms.
• heterocyclic derivatives of the present invention can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess Factor Xa inhibitory activity.
• optically active or racemic forms by virtue of one or more asymmetric carbon atoms
• the invention encompasses any such optically active or racemic form which possesses Factor Xa inhibitory activity.
• the synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form.
• A is an optionally substituted 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 ring nitrogen atoms.
• A is a pyridyl, pyrimidinyl or pyridazinyl ring for example 4-pyridyl, 2-pyridyl, 4-pyridazinyl, 5-pyrimidinyl, 4-pyrimidinyl or 3-pyridyl.
• 4-pyrimidinyl 4-pyridazinyl and 4-pyridyl are preferred of which 4-pyrimidinyl and 4-pyridyl are most preferred.
• A is unsubstituted.
• A is substituted by one, two or three atoms or groups selected from halo (for example fluoro, chloro or bromo), oxo, carboxy, trifluoromethyl, cyano, amino, hydroxy, nitro, C 1-4 alkyl (for example methyl or ethyl), C 1- 4 alkoxy (for example methoxy or ethoxy), C 1-4 alkoxycarbonyl, C 1-4 alkylamino (for example methylamino or ethylamino) or di-C 1-4 alkylamino (for example dimethylamino or diethylamino).
• halo for example fluoro, chloro or bromo
• oxo carboxy
• trifluoromethyl cyano
• C 1-4 alkyl for example methyl or ethyl
• C 1- 4 alkoxy for example methoxy or ethoxy
• A may also be present, where possible, on the heteroatom of the ring, such as, for example, N-oxides.
• Preferred substituents are C 1-4 alkyl and halo.
• A is unsubstituted
• B is an optionally substituted phenylene ring wherein the bonds to A and X 1 may suitably be in the meta or para disposition. Preferably the bonds to A and X 1 are in para dispostion, that is B is a para-phenylene group.
• B is unsubstituted.
• B is substituted by one or two substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, C 1-4 alkyl, C 2-4 alkenyl and C 2-4 alkynyl, from the substituent -(CH 2 ) n Y' wherein n is 0-4 and Y' is selected from hydroxy, amino, carboxy, C 1-4 alkoxy, C 2-4 alkenyloxy, C 2-4 alkynyloxy, C 1-4 alkylamino, di-C 1-4 alkylamino, pyrrolidin-1-yl, piperidino, morpholino, thiomorpholino, 1-oxothiomorpholino, 1,1-dioxothiomorpholino, piperazin-1-yl, 4-C 1-4 alkylpiperazin-1-yl, C 1- 4 alkylthio, C 1-4 alkylsulphinyl
• X 1 when T 1 is CH or N, X 1 is CO, SO 2 , or CH 2 or, when T 1 is CH, X 1 in addition is O or S.
• X 1 is CO.
• T 1 is directly attached to the groups X 1 and L 1 and T 2 is directly attached to the groups L 1 and X 2 .
• L 1 is C 1-4 alkylene for example methylene, ethylene or propylene (preferably ethylene) or is C 1-3 alkylenecarbonyl for example methylenecarbonyl (-CH 2 CO-).
• R 2 is hydrogen or C 1-4 alkyl for example methyl or ethyl.
• R 3 is hydrogen or C 1-4 alkyl for example methyl or ethyl.
• R 2 and R 3 are joined to form a C 1-4 alkylene group, for example a methylene, ethylene or propylene group (preferably ethylene), or a methylenecarbonyl (-CH 2 CO-) group.
• R 2 and R 3 are joined to form, together with T 1 , T 2 and L 1 , a heterocyclic ring wherein at least one of T 1 and T 2 is N.
• heterocyclic rings are piperazine (wherein T 1 and T 2 are both N), piperidine (wherein either T 1 or T 2 is N and the other is CH) and pyrrolidine (wherein either T 1 or T 2 is N and other is CH).
• the heterocyclic ring formed by R and R 1 is piperazine.
• the heterocyclic ring formed by T 1 , T 2 , L 1 , R 2 and R 3 is unsubstituted.
• this ring is substituted by one or two substituents selected from hydroxy, oxo, carboxy and C 1-4 alkoxycarbonyl; or one of the following: -(CH 2 ) n -R, -(CH 2 ) n -NRR 1 , -CO-R , -CO-NRR 1 , -(CH 2 ) n -CO-R and -(CH 2 ) n -CO-NRR 1 ; wherein n is 0, 1 or 2, preferably n is 1 or 2; R and R 1 are independently selected from hydrogen, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, hydroxyC 1-4 alkyl, carboxyC 1-4 alkyl and C 1-4 alkoxycarbonylC 1-4 alkyl or where possible R and R 1 may together form
• the heterocyclic ring formed by R and R 1 are preferably selected from 1-pyrrolidinyl, 1-imidazolinyl, 1-piperidino, 1-piperazinyl, 4-morpholino and 4-thiomorpholino.
• the heterocyclic ring formed by R and R 1 may be unsubstituted.
• the ring formed by R and R 1 is substituted by 1 or 2 substituents selected from oxo, hydroxy and carboxy.
• the heterocyclic ring formed by T 1 , T 2 , L 1 , R 2 and R 3 is substituted by oxo, carboxy, C 1-4 alkoxy or C 1-4 alkoxycarbonyl.
• the heterocyclic ring formed by T 1 , T 2 , L 1 , R 2 and R 3 is unsubstituted.
• X 2 is SO 2 , CH 2 or CO.
• X 2 is SO 2. .
• Q is unsubstituted.
• Q is substituted by one, two or three substituents selected from halo, trifluromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, trifluoromethylsulphonyl, carboxy, carbamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2- 4 alkynyl, C 1-4 alkoxy, C 2-4 alkenyloxy, C 2-4 alkynyloxy, C 1-4 alkylthio, C 1-4 alkylsulphinyl, C 1- 4 alkylsulphonyl, C 1-4 alkylamino, di-C 1-4 alkylamino, C 1-4 alkoxycarbonyl, N -C 1- 4 alkylcarbamoyl, N , N -di-C 1-4 alkylcarbamoyl, C 2-4 alkanoylamino, hydroxyC 1- 4
• a suitable value for Q when it is naphthyl is, for example, 1-naphthyl or 2-naphthyl; when it is phenyl-C 1-4 alkyl is, for example, benzyl, phenethyl and 3-phenylpropyl, when it is phenyl-C 2-4 alkenyl is, for example, styryl, cinnamyl or 3-phenylprop-2-enyl; and when it is phenyl-C 2-4 alkynyl is, for example, 2-phenylethynyl, 3-phenylprop-2-ynyl and 3-phenylprop-1-ynyl.
• Q is naphthyl in particular 2-naphthyl.
• a suitable value for Q when it is a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur is, for example, a 5- or 6-membered heterocyclic moiety which is a single ring or is fused to one or two benzo rings such as furyl, benzofuranyl, tetrahydrofuryl, chromanyl, thienyl, benzothienyl, pyridyl, piperidino, quinolyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolyl, 1,2,3,4-tetrahydroisoquinolinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pyrrolyl, pyrrolidinyl, indolyl, indolinyl, imidazolyl, benzimidazo
• a suitable value for the heteroaryl substituent on Q or the heteroaryl group in a heteroaryl-containing substituent on Q which comprises a 5- or 6-membered monocyclic heteroaryl ring containing up to 3 heteroatoms selected from oxygen, nitrogen and sulphur is, for example, furyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, furazanyl and thiadiazolyl which may be attached through any available position including, for an appropriate X 2 group such as, for example, SO 2 , C(R 5 ) 2 or CO, through any available nitrogen atom, and which may be up to three substituents as defined hereinabove including
• a preferred class of compounds of the present invention is that wherein:
• Particular compounds of the invention include:
• Particularly preferred compounds of the invention are;
• a heterocyclic derivative of the formula I, or pharmaceutically-acceptable salt thereof may be prepared by any process known to be applicable to the preparation of related compounds. Such procedures are provided as a further feature of the invention and are illustrated by the following representative processes in which, unless otherwise stated A, B, X 1 , T 1 , T 2 , L 1 , R 2 , R 3 , X 2 and Q have any of the meanings defined hereinbefore wherein any functional group, for example amino, alkylamino, carboxy or hydroxy, is optionally protected by a protecting group which may be removed when necessary.
• Necessary starting materials may be obtained by standard procedures of organic chemistry.
• the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, which comprises:
• a suitable oxidising agent is, for example, any agent known in the art for the oxidation of thio to sulphinyl and/or sulphonyl, for example, hydrogen peroxide, a peracid (such as 3-chloroperoxybenzoic or peroxyacetic acid), an alkali metal peroxysulphate (such as potassium peroxymonosulphate), chromium trioxide or gaseous oxygen in the presence of platinum.
• the oxidation is generally carried out under as mild conditions as possible and with the required stoichiometric amount of oxidising agent in order to reduce the risk of over oxidation and damage to other functional groups.
• reaction is carried out in a suitable solvent or diluent such as methylene chloride, chloroform, acetone, tetrahydrofuran or tert -butyl methyl ether and at a temperature, for example, at or near ambient temperature, that is in the range 15 to 35°C.
• suitable reagents and conditions are described in, for example, Page G. O.; Synth. Commun. 23 , (1993) 6, 765-769.
• a milder oxidising agent may also be used, for example sodium or potassium metaperiodate, conveniently in a polar solvent such as acetic acid or ethanol.
• Compounds of formula (II) wherein T 2 is N may be prepared by the reaction of a compound of the formula (XI) P-N-(R 2 )-L 1 -NH(R 3 ) , wherein P is a protecting group, with a compound of formula (IX), as defined above, in an analogous manner as described above in method (f) above, and subsequently removing the protecting group.
• compounds of formula (II) may be prepared in an analogous manner as described above in methods (h) and (i).
• Compounds of formula (III) may be prepared by the coupling of a compound of formula (XII), wherein Z is a displaceable group, preferably halo, Z-B-COOH with an activated derivative of ring A as described, for example, in method (d) above.
• the reaction is catalysed with a palladium catalyst as described in Example 1 (c) and Example 3 (a) below.
• Suitable reagents and conditions are described in Martin A.R.; Acta.Chem.Scand., 47 , 221-230, (1993); Mitchell T.N.; Synthesis, 803, (1992) and Stille, J.K., Angew. Chem. Int. Ed. Engl. 25 , 508-524, (1986).
• Suitable non-catalysed coupling reactions include those described in Shiao, M-J. et. al., Synlett., 655, (1992).
• compounds of formula (III) may be prepared by forming A rings on compounds of formula (XII), wherein Z is a functional group capable of cyclisation, by cyclisation reaction.
• Suitable reagents and conditions are described in Bredereck H. Chem.Ber.; 96 , 1505, (1963); Fuchigami, T., Bull. Chem. Soc. Jpn., 49 , p3607, (1976); Huffman, K.R., J. Org. Chem., 28 , p1812, (1963); Palusso, G., Gazz. Chim. Ital., 90 , p1290, (1960) and Ainsworth C.J., Heterocycl.
• Compounds of formula (XIII) may be prepared by the reaction of a compound of the formula (XIV) Z-T 1 (R 2 )-L 1 -N(R 3 )P , wherein Z is a displaceable group or hydrogen and P is a protecting group in an analogous manner is described in method (a), (b) and (c) above and subsequently effecting removal of the protecting group.
• Compounds of formula (VIII) may be prepared by the reaction of a compound of formula (XV) Z-T 1 (R 2 )-L 1 -N(R 3 )P wherein Z is a displaceable group or hydrogen and P is a protecting group, in an analogous method as described in method (a),(b) and (c) above and subsequently effecting removal of the protecting group.
• a pharmaceutically-acceptable salt of a compound of the formula (I) When a pharmaceutically-acceptable salt of a compound of the formula (I) is required, it may be obtained, for example, by reaction of said compound with a suitable acid or base using a conventional procedure.
• an optically active form of a compound of the formula (I) When an optically active form of a compound of the formula (I) is required, it may be obtained, for example, by carrying out one of the aforesaid procedures using an optically active starting material or by resolution of a racemic form of said compound using a conventional procedure, for example by the formation of diastereomeric salts, use of chromatographic techniques, conversion using chirally specific enzmatic processes, or by additon of temporary extra chiral groupd to aid seperation.
• the compounds of the formula (I) are inhibitors of the enzyme Factor Xa.
• the effects of this inhibition may be demonstrated using one or more of the standard procedures set out hereinafter:-
• Fasted male Alderley Park rats 300-450 g are pre-dosed by oral gavage (5 mls/kg) with compound or vehicle (5% DMSO/PEG200) at various times before being anaesthetised with Intraval® (120 mg/kg i.p.).
• Intraval® 120 mg/kg i.p.
• the left jugular vein and the right carotid artery are exposed and cannulated.
• a 1 mL blood sample is taken from the carotid canular into 3.2% trisodium citrate.
• 0.5 mL of the whole blood is then treated with EDTA and used for platelet count determination whilst the remainder is centrifuged (5 mins, 20000g) and the resultant plasma frozen for subsequent drug level, fibrinogen or thrombin antithrombin (TAT) complex determinations.
• Recombinant human tissue factor (Dade Innovin Cat.B4212-50), reconstituted to the manufacturers specification, is infused (2 mL/kg/hr) into the venous canular for 60 minutes.
• a 2 mL blood sample is taken and platelet count, drug level, plasma fibrinogen concentration and TAT complex are determined as before. Platelet counting is performed using at Coulter T540 blood analyser.
• Plasma fibrinogen and TAT levels are dertermining using a clotting assay (Sigma Cat.880-B) and TAT ELISA (Behring) respectively.
• the plasma concentration of the compound is bioassayed using human Factor Xa and a chromogenic substrate S2765 (Kabi), extrapolated from a standard curve (Fragmin) and expressed in Anti-Factor Xa units.
• the data is analysed as follows; tissue factor-induced reductions in platelet count are normalised with respect to pre-dose platelet count and drug activity expressed as a percent inhibition of tissue factor-induced thrombocytopenia when compared to vehicle treated animals.
• Compounds are active if there is statistically significant (p ⁇ 0.05) inhibition of TF-induced thrombocytopenia.
• test compound is administered intravenously or orally to a group of Alderley Park Wistar rats. At various times thereafter animals are anaesthetised, blood is collected and PT coagulation assays analogous to those described hereinbefore are conducted.
• Thrombus formation is induced using an analogous method to that described by Vogel et al ., Thromb. Research , 1989, 54 , 399-410.
• a group of Alderley Park Wistar rats is anaesthetised and surgery is performed to expose the vena cava. Collateral veins are ligated and two loose sutures are located, 0.7 cm apart, round the inferior vena cava.
• Test compound is administered intravenously or orally.
• tissue thromboplastin (30 ⁇ l/kg) is administered via the jugular vein and, after 10 seconds, the two sutures are tightened to induce stasis within the ligated portion of vena cava. After 10 minutes the ligated tissue is excised and the thrombus therein is isolated, blotted and weighed.
• a feature of the invention is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in medical therapy.
• a pharmaceutical composition which comprises a heterocyclic derivative of the formula (I), or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.
• the composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension.
• the above compositions may be prepared in a conventional manner using conventional excipients.
• the amount of active ingredient (that is a heterocyclic derivative of the formula (I), or a pharmaceutically-acceptable salt thereof) that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
• a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active. agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
• Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
• a heterocyclic derivative of formula (I), or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
• the invention also includes the use of such an active ingredient in the production of a medicament for use in:-
• the invention also includes a method of producing an effect as defined hereinbefore or treating a disease or disorder as defined hereinbefore which comprises administering to a warm-blooded animal requiring such treatment an effective amount of an active ingredient as defined hereinbefore.
• the size of the dose for therapeutic or prophylactic purposes of a compound of the formula (I) will naturally vary according to the nature and severity of the medical condition, the age and sex of the animal or patient being treated and the route of administration, according to well known principles of medicine.
• compounds of the formula (I) are useful in the treatment or prevention of a variety of medical disorders where anticoagulant therapy is indicated.
• a compound of the formula (I) for such a purpose it will generally be administered so that a daily oral dose in the range, for example, 0.5 to 100 mg/kg body weight/day is received, given if required in divided doses.
• lower doses will be administered when a parenteral route is employed, for example a dose for intravenous administration in the range, for example, 0.01 to 10 mg/kg body weight/day will generally be used.
• lower doses will be employed, for example a daily dose in the range, for example, 0.1 to 10 mg/kg body weight/day.
• a preferred dose range for either oral or parenteral administration would be 0.01 to 10 mg/kg body weight/day.
• the compounds of formula (I) are primarily of value as therapeutic or prophylactic agents for use in warm-blooded animals including man, they are also useful whenever it is required to produce an anticoagulant effect, for example during the ex-vivo storage of whole blood or in the development of biological tests for compounds having anticoagulant properties.
• the compounds of the invention may be administered as a sole therapy or they may be administered in conjunction with other pharmacologically active agents such as a thrombolytic agent, for example tissue plasminogen activator or derivatives thereof or streptokinase.
• a thrombolytic agent for example tissue plasminogen activator or derivatives thereof or streptokinase.
• the compounds of the invention may also be administered with, for example, a known platelet aggregation inhibitor (for example aspirin, a thromboxane antagonist or a thromboxane synthase inhibitor), a known hypolipidaemic agent or a known anti-hypertensive agent.
• the acid chloride was suspended in dichloromethane (100mL) and 1-(6-bromonaphth-2-ylsulphonyl)piperazine hydrochloride (0.545g, 1.5mmol) added as a solid in two portions followed by triethylamine (2.2mL, 15mmol). The reaction mixture was stirred overnight at room temperature then concentrated in vacuo . The resulting solid was separated between ethyl acetate (100mL) and water (2x100mL).
• reaction mixture was diluted with ethyl acetate (50mL) and washed twice with saturated aqueous sodium hydrogen carbonate solution (2x50mL). The organic layer was dried over MgSO 4 , filtered and concentrated in vacuo .
• 6-Bromonaphth-2-ylsulphonyl chloride (470mg) was added in one portion to a mixture of 1-[2-methoxycarbonyl-4-(4-pyridyl)benzoyl]piperazine (500mg) and triethylamine (311mg) in dichloromethane (5ml) at ambient temperature. After 10 minutes the mixture was reduced in vacuo and the residue thus obtained purified by flash chromatography at 3psi on silica (Merck ART 9385) eluting first with dichloromethane, then 1% and 2% v/v methanol in dichloromethane.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Diabetes (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (5)

Related Parent Applications (1)

Publications (1)

Family

ID=26310361

Family Applications (2)

Family Applications After (1)

Country Status (28)

Families Citing this family (43)

Citations (4)

Family Cites Families (53)

• 1997
  • 1997-04-11 UA UA99063121A patent/UA56197C2/uk unknown
  • 1997-11-04 AU AU48748/97A patent/AU731929B2/en not_active Ceased
  • 1997-11-04 PT PT97911333T patent/PT937048E/pt unknown
  • 1997-11-04 DK DK97911333T patent/DK0937048T3/da active
  • 1997-11-04 BR BR9712672-1A patent/BR9712672A/pt not_active Application Discontinuation
  • 1997-11-04 KR KR1019990704055A patent/KR20000053128A/ko active Search and Examination
  • 1997-11-04 DE DE69727308T patent/DE69727308T2/de not_active Expired - Lifetime
  • 1997-11-04 IL IL12970697A patent/IL129706A/en not_active IP Right Cessation
  • 1997-11-04 EP EP03011815A patent/EP1358909A1/fr not_active Withdrawn
  • 1997-11-04 WO PCT/GB1997/003033 patent/WO1998021188A1/fr active IP Right Grant
  • 1997-11-04 HU HU0001098A patent/HUP0001098A3/hu unknown
  • 1997-11-04 CZ CZ0163499A patent/CZ296342B6/cs not_active IP Right Cessation
  • 1997-11-04 EP EP97911333A patent/EP0937048B1/fr not_active Expired - Lifetime
  • 1997-11-04 YU YU20999A patent/YU20999A/sh unknown
  • 1997-11-04 SK SK613-99A patent/SK284665B6/sk unknown
  • 1997-11-04 CN CNB971994269A patent/CN1220682C/zh not_active Expired - Fee Related
  • 1997-11-04 TR TR1999/01006T patent/TR199901006T2/xx unknown
  • 1997-11-04 NZ NZ334710A patent/NZ334710A/xx unknown
  • 1997-11-04 ES ES97911333T patent/ES2213208T3/es not_active Expired - Lifetime
  • 1997-11-04 US US09/297,768 patent/US6300330B1/en not_active Expired - Fee Related
  • 1997-11-04 RU RU99112135/04A patent/RU2213732C2/ru not_active IP Right Cessation
  • 1997-11-04 JP JP52227498A patent/JP2001504113A/ja not_active Ceased
  • 1997-11-04 AT AT97911333T patent/ATE258167T1/de not_active IP Right Cessation
  • 1997-11-04 CA CA002266890A patent/CA2266890A1/fr not_active Abandoned
  • 1997-11-04 PL PL97333241A patent/PL189703B1/pl not_active IP Right Cessation
  • 1997-11-05 TW TW086116467A patent/TW458968B/zh not_active IP Right Cessation
  • 1997-11-06 MY MYPI97005268A patent/MY124122A/en unknown
• 1999
  • 1999-05-07 NO NO19992230A patent/NO312894B1/no unknown
  • 1999-05-25 BG BG103430A patent/BG64258B1/bg unknown
• 2001
  • 2001-09-27 US US09/963,686 patent/US6936610B2/en not_active Expired - Fee Related
• 2003
  • 2003-05-21 RU RU2003115094/04A patent/RU2003115094A/ru not_active Application Discontinuation

Patent Citations (4)

Also Published As

Similar Documents

Legal Events